Financial Snapshot

Revenue
$28.81M
TTM
Gross Margin
85.54%
TTM
Net Earnings
-$26.41M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
267.09%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$11.43M
Q3 2024
Cash
Q3 2024
P/E
-39.25
Nov 29, 2024 EST
Free Cash Flow
-$57.10M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022
Revenue $45.23M $25.92M
YoY Change 74.47%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022
Revenue $45.23M $25.92M
Cost Of Revenue $7.062M $4.430M
Gross Profit $38.16M $21.49M
Gross Profit Margin 84.38% 82.91%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022
Selling, General & Admin $59.21M $50.27M
YoY Change 17.78%
% of Gross Profit 155.15% 233.9%
Research & Development $8.995M $7.243M
YoY Change 24.19%
% of Gross Profit 23.57% 33.7%
Depreciation & Amortization $847.0K $497.0K
YoY Change 70.42%
% of Gross Profit 2.22% 2.31%
Operating Expenses $68.20M $57.51M
YoY Change 18.59%
Operating Profit -$30.04M -$36.02M
YoY Change -16.6%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022
Interest Expense -$2.098M -$1.603M
YoY Change 30.88%
% of Operating Profit
Other Income/Expense, Net $2.686M $462.0K
YoY Change 481.39%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022
Pretax Income -$29.45M -$37.16M
YoY Change -20.74%
Income Tax $11.00K $2.000K
% Of Pretax Income
Net Earnings -$29.46M -$37.16M
YoY Change -20.72%
Net Earnings / Revenue -65.15% -143.37%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.87 -$1.09

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022
Cash & Short-Term Investments $34.50M $68.24M
YoY Change -49.45%
Cash & Equivalents $34.50M $68.24M
Short-Term Investments
Other Short-Term Assets $2.130M $1.165M
YoY Change 82.83%
Inventory $5.868M $4.075M
Prepaid Expenses
Receivables $9.470M $6.324M
Other Receivables $0.00 $0.00
Total Short-Term Assets $51.96M $79.80M
YoY Change -34.88%
Property, Plant & Equipment $4.222M $4.361M
YoY Change -3.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.499M $1.346M
YoY Change 11.37%
Total Long-Term Assets $6.959M $6.659M
YoY Change 4.51%
Total Assets $58.92M $86.46M
YoY Change
Accounts Payable $732.0K $423.0K
YoY Change 73.05%
Accrued Expenses $8.122M $6.327M
YoY Change 28.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $11.83M $2.500M
YoY Change 373.32%
Total Short-Term Liabilities $21.60M $9.864M
YoY Change 118.98%
Long-Term Debt $0.00 $12.72M
YoY Change -100.0%
Other Long-Term Liabilities $2.162M $2.860M
YoY Change -24.41%
Total Long-Term Liabilities $2.162M $15.58M
YoY Change -86.12%
Total Liabilities $23.76M $25.44M
YoY Change -6.61%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.0368 Billion

About Ceribell, Inc.

CeriBell Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Sunnyvale, California. The company went IPO on 2024-10-11. Ceribell, Inc. is a commercial-stage medical technology company. The company is focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Point-of-Care EEG enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies. Its Clarity AI algorithm interprets EEG in real-time, provides bedside alerts and continuous monitoring for status epilepticus. The Ceribell EEG Portal makes it easy to remotely review EEG in real-time with pre-annotated EEG insights.

Industry: Electromedical & Electrotherapeutic Apparatus Peers: